Familial/Genetic Leukemia Syndromes: Impact on Patient Care
Clinicians need education regarding which patients with leukemia are candidates for genetic counseling and testing and how the management of patients with known germline mutations is affected. This knowledge will help clinicians provide these patients with optimal care.
Category
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Chronic Myelogenous Leukemia
  • Leukemia
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Management of Chronic Phase Chronic Myeloid Leukemia with Resistance to Multiple TKIs
In the majority of patients responding to TKI therapy, chronic myeloid leukemia (CML) is now managed like a chronic disease. However, it poses significant challenges to the clinicians in terms of selection of alternate TKI therapy in patients with inadequate initial response to initial TKI therapy. Informing clinicians about the recent FDA approvals would assist in the incorporation of new treatment options into their routine clinical practice to improve patient outcomes.
Category
  • Chronic Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Chronic Myeloid Leukemia/Myelofibrosis: TKI Therapy and Toxicity Management
There is a continuing need to educate clinicians about the differences in toxicity profiles between TKIs and the various strategies that are being evaluated in clinical trials to mitigate the risk of adverse events associated with TKI therapy for CML and MPN.
Category
  • Chronic Myelogenous Leukemia
  • Myeloproliferative Neoplasms
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation